CTI BioPharma Corp.

NasdaqCM:CTIC Stock Report

Market Cap: US$1.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma Management

Management criteria checks 3/4

CTI BioPharma's CEO is Adam Craig, appointed in Mar 2017, they has a tenure of 6.25 years. Their total yearly compensation is $4.59M , comprised of 14.3% salary and 85.7% bonuses, including company stock and options. They directly owns 0.022% of the company’s shares, worth $267.56K. The average tenure of the management team and the board of directors is 6 years and 6.3 years respectively.

Key information

Adam Craig

Chief executive officer

US$4.6m

Total compensation

CEO salary percentage14.3%
CEO tenure6.3yrs
CEO ownership0.02%
Management average tenure6yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Aug 17

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

Aug 08

CTI BioPharma: Approval Is Great, Now There's The Follow Through

Jul 19

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Jul 07

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

May 04

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

Apr 11

CTI BioPharma: A Speculative Buy Into The PDUFA Date

Mar 01

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

Dec 24

FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA

Jun 01

CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis

May 06

CTI BioPharma: Accelerated Approval Pathway Looks Attractive

Dec 06

CEO Compensation Analysis

How has Adam Craig's remuneration changed compared to CTI BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$69m

Dec 31 2022US$5mUS$657k

-US$93m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$121m

Mar 31 2022n/an/a

-US$118m

Dec 31 2021US$2mUS$633k

-US$98m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$58m

Dec 31 2020US$3mUS$615k

-US$52m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$44m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$595k

-US$40m

Sep 30 2019n/an/a

-US$31m

Jun 30 2019n/an/a

-US$36m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$3mUS$564k

-US$29m

Sep 30 2018n/an/a

-US$45m

Jun 30 2018n/an/a

-US$42m

Mar 31 2018n/an/a

-US$29m

Dec 31 2017US$6mUS$434k

-US$45m

Compensation vs Market: Adam's total compensation ($USD4.59M) is about average for companies of similar size in the US market ($USD3.55M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.

CEO

Adam Craig (57 yo)

6.3yrs

Tenure

US$4,592,646

Compensation

Dr. Adam R. Craig, M.D., Ph D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv...

Leadership Team

NamePositionTenureCompensationOwnership
Adam Craig
President6.3yrsUS$4.59m0.022%
$ 267.6k
David Kirske
Executive VP5.8yrsUS$1.47m0.013%
$ 155.7k
James Fong
Executive VP & Chief Commercial Officerno dataUS$597.30k0.0027%
$ 32.4k
Ed Bell
Senior Director of Investor Relations15yrsno datano data
Bruce Bennett
Senior Vice President Global Pharmaceutical Operationsno datano datano data
John Volpone
Executive VP & Chief of Staffno datano datano data
Jennifer Smith
Senior Vice President of Biometrics4.6yrsno datano data

6.0yrs

Average Tenure

65yo

Average Age

Experienced Management: CTIC's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Adam Craig
President6.3yrsUS$4.59m0.022%
$ 267.6k
Diane Parks
Independent Director1.8yrsUS$301.12k0%
$ 0
Daniel Von Hoff
Chairman of Scientific Advisory Board9.9yrsno datano data
Laurent Fischer
Independent Chairman of the Board5.9yrsUS$352.12k0%
$ 0
David Parkinson
Independent Director6yrsUS$317.62k0%
$ 0
Matthew Perry
Independent Director7.4yrsUS$303.62k0.033%
$ 392.1k
Reed Tuckson
Independent Director11.8yrsUS$319.12k0.037%
$ 442.1k
Michael Metzger
Independent Director6.4yrsUS$330.62k0%
$ 0

6.3yrs

Average Tenure

65yo

Average Age

Experienced Board: CTIC's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/28 17:13
End of Day Share Price 2023/06/23 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CTI BioPharma Corp. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Fabrizio SpagnaAxia Financial Research
Leah Rush CannBrookline Capital Markets
null nullBTIG